Stockscreener 앱 받기
1.62
1.57%
0.025
전일 마감가:
$1.595
열려 있는:
$1.59
하루 거래량:
9,540
Relative Volume:
0.07
시가총액:
$37.24M
수익:
$48.20M
순이익/손실:
$-35.05M
주가수익비율:
-1.0336
EPS:
-1.5673
순현금흐름:
$-13.02M
1주 성능:
+3.58%
1개월 성능:
+17.39%
6개월 성능:
+4.52%
1년 성능:
-50.76%
1일 변동 폭
$1.58
$1.625
1주일 범위
$1.46
$1.65
52주 변동 폭
$1.06
$5.22
Celularity Inc Stock (CELU) Company Profile
명칭
Celularity Inc
전화
(908) 768-2170
주소
170 PARK AVE, FLORHAM PARK
CELU을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.61 | 37.24M | 48.20M | -35.05M | -13.02M | -1.5673 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.00 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.32 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.46 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.20 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.47 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-30 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 개시 | H.C. Wainwright | Buy |
| 2022-04-06 | 다운그레이드 | Truist | Buy → Hold |
| 2022-01-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Celularity Inc 주식(CELU)의 최신 뉴스
Celularity (CELU) Resolves Nasdaq Fee Issue to Avoid Delisting | - GuruFocus
Celularity (NASDAQ:CELU) Stock Price Down 4.7% – Time to Sell? - Defense World
Celularity pays $70,000 fee to Nasdaq following receipt of notice - MSN
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - The Manila Times
Celularity Inc. Faces Potential Delisting from Nasdaq Due to Fee and Filing Delinquencies - Nasdaq
Celularity Given Until May 1 to Address Dual Nasdaq Compliance Issues or Face Delisting - Stock Titan
Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com Canada
Celularity faces Nasdaq delisting over late filing - Investing.com
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times
CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan
Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology - The Globe and Mail
Celularity Delays Yearly Report Filing Amid Financial Challenges - TipRanks
Celularity extends debt maturity, issues stock to investor By Investing.com - Investing.com Australia
Celularity enters into standby equity purchase agreement with Ya Ii Pn -March 21, 2025 at 04:39 pm EDT - MarketScreener
Celularity enters into standby equity purchase agreement with Ya Ii Pn - TradingView
Robust Growth in Regenerative Placental Cell Therapy Market - openPR.com
Celularity receives FDA TRG recommendation letters for Natalin, Acelagraft - MSN
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges - Investing.com Australia
CELU Stock Touches 52-Week Low at $1.29 Amid Market Challenges By Investing.com - Investing.com South Africa
Celularity Enters Strategic Collaboration Agreement with BlueSphere Bio to Support Cell Therapy Manufacturing - Defense World
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products - The Manila Times
Celularity Secures Crucial FDA Pathway for Wound Care ProductsCan They Capture Share of $810M Market? - StockTitan
Celularity inks manufacturing deal with BlueSphere Bio By Investing.com - Investing.com Australia
Celularity inks manufacturing deal with BlueSphere Bio - Investing.com
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company - The Manila Times
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential? - StockTitan
Celularity Inc.'s (NASDAQ:CELU) Business And Shares Still Trailing The Industry - Simply Wall St
Celularity Inc. Extends Loan Agreements with Resorts World Inc and C.V. Starr & Co. - Defense World
SEC Form FWP filed by Celularity Inc. - Quantisnow
Celularity Inc (CELU) Stock: Analyzing the Market Value - The News Heater
Celularity Inc (CELU) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Placental Stem Cell Therapy Solution Market Size And Booming - openPR
Celularity files to sell 6.52M shares of Class A common stock, warrants - MSN
Celularity cancels material agreement with investor - MSN
Celularity amends warrant terms, secures $2.46 million funding By Investing.com - Investing.com Canada
Celularity amends warrant terms, secures $2.46 million funding - Investing.com India
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs - The Manila Times
Celularity cancels material agreement with investor By Investing.com - Investing.com
Celularity Faces Challenges as Agreement Expires - TipRanks
Celularity Inc. (NASDAQ:CELU) Short Interest Up 7.1% in December - Defense World
Celularity Inc (CELU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celularity Inc 주식 (CELU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hariri Robert J | Chief Executive Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
3,281 |
0 |
21,482 |
| Haines John R | Senior Exec Vice President |
Apr 13 '25 |
Option Exercise |
0.00 |
1,641 |
0 |
29,698 |
| Beers David C | Chief Financial Officer |
Apr 13 '25 |
Option Exercise |
0.00 |
1,025 |
0 |
18,561 |
| Brigido Stephen | Pres., Functional Regeneration |
Feb 17 '25 |
Option Exercise |
0.00 |
10,000 |
0 |
11,641 |
| Beers David C | Chief Financial Officer |
Feb 17 '25 |
Option Exercise |
0.00 |
12,500 |
0 |
21,932 |
| Haines John R | Senior Exec Vice President |
Feb 17 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
35,092 |
0.37%
0.04%
자본화:
|
볼륨(24시간):